Catheter-based renal denervation: The next chapter begins

Abstract

With the publication of the most recent well-designed and rigorously executed proof-of-concept trials, convincing evidence is accumulating to indicate that catheter-based renal denervation is indeed an effective antihypertensive strategy with or without concomitant antihypertensive medication. Further studies with designs relevant to clinical reality also taking into account patient preference will be needed to ultimately establish the position of new device-based treatment approaches in the armamentarium of antihypertensive therapy. The next chapter begins-stay tuned. Conflict of interest: This work was supported by research grants of Medtronic, Recor Medical and St. Jude Medical (now Abbott). F.M. and M.B. are supported by Deutsche Gesellschaft fur Kardiologie, Deutsche Hochdruckliga, and Deutsche Forschungsgemeinschaft (SFB TRR 219) and have received grant support and personal fees from Medtronic and Recor Medical. M.P.S. is supported by an NHMRC Research Fellowship and has received consulting fees, and/ or travel and research support from Medtronic, Abbott, Novartis, Servier, Pfizer and Boehringer-Ingelheim. M.B. has received honoraria for scientific advisory activities and study committee membership from Astra-Zeneca, Boehringer-Ingelheim, Servier, and Vifor. M.E. receives salary support in the form of a Senior Principal Research Fellowship from the National Health and Medical Research Council of Australia. He has received personal fees from Medtronic. Outside this work TFL has received educational grants of AstraZeneca, Daichi-Sankyo and the Menarini Foundation.